• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Varenicline tartrate
    Varenicline tartrate
    Information
    CAS No. 375815-87-5 Price $218 / 5mg
    Catalog No.CFN90008Purity>=98%
    Molecular Weight361.35Type of CompoundAlkaloids
    FormulaC13H13N3.C4H6O6Physical DescriptionPowder
    Download     COA    MSDS    SDFSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • National Chung Hsing University (Taiwan)
  • Leibniz Institute of Plant Bioch... (Germany)
  • Warszawski Uniwersytet Medyczny (Poland)
  • Uniwersytet Gdański (Poland)
  • Universit?t Basel (Switzerland)
  • Washington State University (USA)
  • Universidad Veracuzana (Mexico)
  • Biotech R&D Institute (USA)
  • University of Limpopo (South Africa)
  • University of Indonesia (Indonesia)
  • Indian Institute of Science (India)
  • More...
  • Package
    Featured Products
    Isoquercitrin

    Catalog No: CFN98753
    CAS No: 482-35-9
    Price: $80/20mg
    Echinacoside

    Catalog No: CFN98105
    CAS No: 82854-37-3
    Price: $90/20mg
    Isoliquiritin apioside

    Catalog No: CFN90800
    CAS No: 120926-46-7
    Price: $338/10mg
    Morusinol

    Catalog No: CFN97086
    CAS No: 62949-93-3
    Price: $668/10mg
    Narcissoside

    Catalog No: CFN99773
    CAS No: 604-80-8
    Price: $368/20mg
    Varenicline tartrate Description
    Source:
    Biological Activity or Inhibitors: 1. Varenicline significantly reduces alcohol consumption and craving, making it a potentially viable option for the treatment of alcohol dependence.
    2. Varenicline tartrate appears to be a safe and well-tolerated opportunistic treatment for inpatient smokers who have related chronic disease, suggests it be considered as part of standard care in the hospital setting.
    Solvent: Pyridine, Methanol, Ethanol, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.7674 mL 13.837 mL 27.674 mL 55.348 mL 69.185 mL
    5 mM 0.5535 mL 2.7674 mL 5.5348 mL 11.0696 mL 13.837 mL
    10 mM 0.2767 mL 1.3837 mL 2.7674 mL 5.5348 mL 6.9185 mL
    50 mM 0.0553 mL 0.2767 mL 0.5535 mL 1.107 mL 1.3837 mL
    100 mM 0.0277 mL 0.1384 mL 0.2767 mL 0.5535 mL 0.6919 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Varenicline tartrate References Information
    Citation [1]

    Nicotine Tob Res. 2014 Nov;16(11):1495-502.

    Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study).[Pubmed: 25031315]
    INTRODUCTION: Inpatient medical settings offer an opportunistic environment for initiating smoking cessation interventions to patients reflecting on their health. Current evidence has shown the superior efficacy of Varenicline tartrate (VT) for smoking cessation compared with other tobacco cessation therapies; however, recent evidence also has highlighted concerns about the safety and tolerability of Varenicline tartrate. Given these apprehensions, we aimed to evaluate the safety and effectiveness of Varenicline tartrate plus quitline-counseling compared to quitline-counseling alone in the inpatient medical setting. METHODS: Adult patients (n = 392, 20-75 years) admitted with a smoking-related illnesses to 3 hospitals were randomized to receive either 12 weeks of Varenicline tartrate (titrated from 0.5mg daily to 1mg twice daily) plus quitline-counseling (VT+C), (n = 196) or quitline-counseling alone (n = 196). RESULTS: Varenicline tartrate was well tolerated in the inpatient setting among subjects admitted with acute smoking-related illnesses (mean age 52.8±2.89 and 53.7±2.77 years in the Varenicline tartrate+C and counseling alone groups, respectively). The most common self-reported adverse event during the 12-week treatment phase was nausea (16.3% in the Varenicline tartrate+C group compared with 1.5% in the counseling alone group). Thirteen deaths occurred during the study period (n = 6 were in the Varenicline tartrate+C arm compared with n = 7 in the counseling alone arm). All of these subjects had known comorbidities or developed underlying comorbidities. CONCLUSIONS: Varenicline tartrate appears to be a safe and well-tolerated opportunistic treatment for inpatient smokers who have related chronic disease. Based on the proven efficacy of varenicline from outpatient studies and our recent inpatient evidence, we suggest it be considered as part of standard care in the hospital setting.
    Citation [2]

    J Addict Med. 2013 Jul-Aug;7(4):277-86.

    A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.[Pubmed: 23728065]
    OBJECTIVES: To assess the efficacy and safety of Varenicline tartrate (Chantix) for the treatment of alcohol dependence. Varenicline tartrate is a partial α4β2 nicotinic acetylcholine agonist approved by the Food and Drug Administration for smoking cessation. It has reduced drinking in animal studies and in small studies of humans who were both heavy drinkers and smokers. This is the first multisite clinical trial of varenicline in a population of smokers and nonsmokers with alcohol dependence. METHODS: Men and women (n = 200) meeting the criteria for alcohol dependence were recruited across 5 clinical sites. Patients received double-blind varenicline or placebo and a computerized behavioral intervention. Varenicline tartrate was titrated during the first week to 2 mg/d, which was maintained during weeks 2 to 13. RESULTS: The Varenicline tartrate group had significantly lower weekly percent heavy drinking days (primary outcome) (adjusted mean difference = 10.4), drinks per day, drinks per drinking day, and alcohol craving compared with the placebo group (P < 0.05). The average treatment effect on alcohol use was similar for smokers and nonsmokers. Varenicline tartrate was well-tolerated; adverse events were expected and mild. CONCLUSIONS: Varenicline tartrate significantly reduced alcohol consumption and craving, making it a potentially viable option for the treatment of alcohol dependence.
    Citation [3]

    AIDS Patient Care STDS. 2012 Jan;26(1):12-9.

    Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.[Pubmed: 22007690]
    The prevalence of smoking in HIV-infected subjects is high. As a smoking cessation aid, Varenicline tartrate (Champix(®), Pfizer, Saint-Laurent, QC, Canada or Chantix(®), Pfizer, Mission, KS) has not been previously evaluated in HIV-infected smokers. In this multicenter pilot open label study, Varenicline tartrate 1.0 mg was used twice daily for 12 weeks with dose titration in the first week. Adverse events (AEs) during the treatment period were recorded. Changes from baseline in laboratory tests, vital signs, daily cigarette consumption, nicotine dependence, and withdrawal were measured through week 24. Self-reported abstinence was validated by serum cotinine at week 12. We enrolled 36 subjects with a mean of 29 pack-years of smoking and a minimum of 4 cigarettes per day. All but 1 were male, 33 (92%) were white. The most frequently reported AEs were nausea (33%), abnormal dreams (31%), affect lability (19%), and insomnia (19%). Six (17%) subjects discontinued Varenicline tartrate due to AEs. No grade 3/4 laboratory abnormalities or serious AEs occurred during the study. There was no significant change in HIV viral load. CD4 counts increased by 69 cells/mm3 (p = 0.001) at week 24. Serum cotinine-verified 4-week continuous abstinence rate through weeks 9-12 was 42% (95% confidence interval [CI]: 26-58%). AEs and abstinence rates were comparable to those in published randomized controlled trials conducted in generally healthy HIV-negative smokers. Varenicline tartrate was safe and appears effective among HIV-infected smokers in this exploratory study, although AEs were common. The most common AE was nausea, with no adverse effect on HIV treatment outcome. Close monitoring of liver enzymes and blood pressure is recommended for HIV-positive smokers taking varenicline.